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Abstract
Objectives: The role of surgery in stage IV gallbladder (GB) cancer is not well established. This study
analyses prognostic factors in patients with stage IV GB cancer following surgical resection with the aim
of identifying a subgroup of patients who might benefit from surgical resection.
Methods: Clinicopathological details were analysed for 94 patients who were surgically treated for stage
IV GB cancer at Seoul National University Hospital.
Results: Median survival was 8 months in patients with either stage IVa or IVb disease. Sixteen patients
(17.0%) underwent resection with curative intent, which increased overall survival over that in patients
undergoing palliative surgery (P < 0.001). No survival benefit was seen following surgery with curative
intent in patients with stage IVa disease (P = 0.764). Surgery with curative intent resulted in a survival
benefit in patients with stage IVb disease, patients with an isolated liver metastasis near the GB bed
(median survival: 31 months vs. 9 months; P < 0.001) and patients with limited numbers of peritoneal
implantations (median survival: 20 months vs. 6 months; P = 0.002). Preoperative serum carcinoembry-
onic antigen (CEA) (P = 0.018), surgery with curative intent (P = 0.045) and adjuvant chemotherapy
(P = 0.002) were independent prognostic factors in patients with stage IV GB cancer.
Conclusions: Surgery in combination with systemic chemotherapy may be beneficial in carefully
selected patients with stage IVb GB cancer.
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Introduction
Gallbladder (GB) carcinoma is the most frequent of biliary tract
cancers.1 Despite recent advances in diagnostic tools,2,3 a lack of
symptoms or signs in its early stages delays the diagnosis of GB
cancer until the disease is significantly advanced. In patients with
early-stage GB cancer, surgical resection can yield favourable out-
comes,4 but in patients with advanced disease the prognosis is
usually poor.1,5,6
Patients with stage IV GB cancer are known to have a dismal
prognosis,7 even after attempted curative resection.5,6,8,9 Advanced
GB cancer with para-aortic lymph node metastasis or distant
metastasis has been generally considered to represent a contrain-
dication to surgery.6,10 Aggressive surgery that attempts to improve
survival has been described, although no consensus regarding
indications for radical surgery has been reached.8,11–13
The purpose of this study was to analyse factors for survival and
prognosis in patients with stage IV GB cancer following surgical
resection, with the aim of identifying a subset of patients whomay
benefit from surgical resection.
Materials and methods
This study was approved by the institutional review board at Seoul
National University Hospital, which waived requirements for
the provision of informed consent. Clinicopathological data and
radiological images were prospectively collected in electronic
medical record format. From January 1996 to January 2010, 421
patients diagnosed with GB cancer underwent surgery at Seoul
National University Hospital. Gallbladder cancer was diagnosed
using computed tomography (CT); when necessary, magnetic
resonance imaging or positron emission tomography were
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selectively used. Hyperbilirubinaemia was defined as serum total
bilirubin of >5 mg/dl. A serum carbohydrate antigen 19-9
(CA 19-9) level of >37 U/ml was considered to indicate elevated
CA 19-9. Potential negative margin (R0) resections of both the
primary tumour and any metastatic lesions were considered to
represent operations with curative intent. At the beginning of the
operation, the peritoneal cavity was explored to identify distant
metastases. The locations of any distant metastases were specified.
In patients with liver metastases, the sites of liver metastases were
identified according to preoperative imaging and intraoperative
findings. Liver metastases within 3 cm of the GB bed were con-
sidered to be ‘near’ the GB bed. In patients with peritoneal
seeding, peritoneal implantation was identified during the opera-
tion and patients with fewer than three nodules of approximately
2–3 mm in size, without evidence of disseminated metastatic
disease, were considered to have limited peritoneal implantation.
Following surgery, a pathological diagnosis was established
according to the seventh edition of the American Joint Committee
on Cancer (AJCC) staging system.14 Patients were followed in the
outpatient department using tumour markers and CT every 6
months. Recurrences were identified using radiological imaging
and percutaneous biopsy if necessary.
Data were analysed using IBM spss Statistics Version 19.0 (IBM
Corp., Somers, NY, USA). Continuous variables are presented as
medians and ranges. Continuous parameters in each group were
compared using the Mann–Whitney U-test; categorical param-
eters were compared using the chi-squared test or Fisher’s exact
test. Survival analysis was performed using the Kaplan–Meier
method for univariate analysis and the Cox proportional hazard
model for multivariate analysis. A two-sided P-value of0.05 was
accepted as indicating statistical significance and a two-sided
P-value of 0.05–0.10 was accepted as indicating marginal statisti-
cal significance.
Results
Of the 421 patients treated for GB cancer during the study
period, 94 (22.3%) patients who underwent surgery for stage IV
GB cancer were included for further analysis. Clinical, operative
and pathological variables are shown in Table 1. Seventy-one
(75.5%) patients had died by the end of the study; the median
follow-up in those still alive was 8.0 months (range: 1.0–101.0
months). Sixteen patients (17.0%) had stage IVa and 78 patients
(83.0%) had stage IVb disease. Two patients had incidental GB
cancer with peritoneal implantation, which was found during
surgery for cholecystitis.
Surgery with curative intent was performed in 16 patients
(17.0%), in 15 of whom R0 resection was achieved. Palliative
resections were performed in patients with combined cholecystitis
or impending obstruction of the gastrointestinal tract. Surgical
procedures in the 78 (83.0%) patients who underwent palliative
resection included one hepatectomy (1.1%), four extended chole-
cystectomies (4.3%), 58 cholecystectomies (61.7%), eight bypass
operations (8.5%) and seven open biopsies (7.4%). A comparison
of outcomes in patients undergoing curative resection with those
undergoing palliative resection showed no statistical difference in
terms of age (mean age: 48.44 years vs. 47.31 years; P = 0.880),
male : female ratio (1.7 vs. 1.2; P = 0.588), incidence of preopera-
tive hyperbilirubinaemia (three of 16 patients vs. 14 of 78 patients;
P = 0.940) or elevated CA 19-9 (eight of 15 patients vs. 40 of 68
patients; P = 0.697). The curative resection group included a lower
percentage of patients with serum CEA of >5 ng/ml [two of 16
patients (12.5%) vs. 35 of 74 patients (47.3%); P = 0.010] and a
higher proportion of patients treated with adjuvant chemo-
therapy (62.5% vs. 25.6%; P = 0.004). The curative resection rate
was higher in stage IVa (n = 6, 37.5%) than in stage IVb (n = 10,
12.8%) GB cancer (P = 0.027).
Table 1 Demographic and surgical data for the 94 stage IV gallblad-
der cancer patients
Characteristics Values
Age, years, median (range) 62.0 (43.0–82.0)
Sex (male : female) 1 : 1.3
Preoperative serum laboratory test
Bilirubin, mg/dl, median (range) 0.9 (0.3–30.6)
CEA, ng/ml, median (range) 3.5 (0.7–3070.0)
CA 19-9, U/ml, median (range) 31.0 (1.0–80 000.0)
Disease stage, AJCC 7th edition, n (%)
IVa 16 (17.0%)
T4N0 4 (4.3%)
T4N1 7 (7.4%)
T4Nx 5 (5.3%)
IVb 78 (83.0%)
Para-aortic lymph node metastasis 22 (23.4%)
Liver metastasis 20 (21.3%)
Peritoneal implantation 36 (38.3%)
Operation, n (%)
Resection with curative intent 16 (17.0%)
Extended cholecystectomy 6 (6.4%)
Hepatopancreatoduodenectomy 4 (4.3%)
Extended right hemihepatectomy 4 (4.3%)
Whipple's operation and extended
cholecystectomy
1 (1.1%)
Laparoscopic cholecystectomy with
metastasectomy
1 (1.1%)
Palliation 78 (83.0%)
Resection margin status, n (%)
R0 15 (16.0%)
R1 1 (1.0%)
R2 78 (83.0%)
Adjuvant chemotherapy, n (%) 30 (31.9%)
Follow-up, months, median (range) 8.0 (1–101)
CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9;
AJCC, American Joint Committee on Cancer.
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The clinicopathological characteristics of the 16 patients who
underwent surgery with curative intent are shown in Table 2.
Adjuvant chemotherapy was performed more often in patients
who underwent curative resection than in those undergoing pal-
liative surgery (10 of 16 patients vs. 20 of 78 patients; P = 0.004).
Various chemotherapeutic agents were used: 11 patients received
fluorouracil (5-FU)-based chemotherapy; seven received
gemcitabine-based chemotherapy; six received titanium silicate
(TS)-1 based chemotherapy, and four were treated with chemo-
therapy based on miscellaneous agents. The chemotherapeutic
agents used in the other two patients were not identified.
Overallmedian survival in patients with stage IVGB cancer who
underwent surgery was 8 months [95% confidence interval (CI)
7.2–8.8].Median survival after surgerywith curative intent (n= 16)
was significantly higher than that in patients who underwent pal-
liative surgery (n = 78) [median survival: 16.0 months (95% CI
6.2–25.8) vs. 8.0 months (95% CI 6.9–9.1); P < 0.001] (Fig. 1).
Median survival rates in all patients with stage IVa (n = 16) and
stage IVb (n = 78) disease were comparable [8.0 months (95% CI
6.5–9.5) vs. 8.0 months (95% CI 7.1–8.9); P = 0.400]. Of the
patientswhounderwent surgerywith curative intent (n=16), those
with stage IVb disease (n = 10) achieved better survival than those
with stage IVa disease (n = 6) [median survival: 26.0 months (95%
CI 13.6–38.4) vs. 8.0 months (95% CI 6.9–9.1); P < 0.001].
In patients with stage IVa disease, no difference in survival was
noted between those who underwent surgery with curative intent
[n = 6; median survival: 8.0 months (95% CI 6.9–9.1)] and those
who underwent surgical palliation [n = 10; median survival: 9.0
months (95% CI 6.2–11.8)] (P = 0.764). Of the 20 patients with
liver metastases, four patients with one or two isolated liver
metastases near the GB bed underwent curative resection. In
patients with liver metastases, median survival in those who
underwent surgery with curative intent (n = 4; 31.0 months) was
higher than in those who underwent palliative surgery [n = 16;
9.0 months (95% CI 5.3–12.7)] (P < 0.001). Peritoneal implan-
tation was observed in 36 patients at surgery. Five patients with
limited numbers of seeding nodules underwent resection with
curative intent that included the excision of seeding nodules. In
patients with limited peritoneal implantation, median survival
was higher in those who underwent surgery with curative intent
Table 2 Clinicopathological characteristics of 16 patients who underwent resection with curative intent
Stage Age,
years/
sex
Operation T N M Metastasis
site
Survival,
months
Final
status
Chemotherapy Radiation Recurrence
(months)
IVa 80/M HPD 4 0 0 5 Dead - - Liver (4)
67/M HPD and
colectomy
4 0 0 9 Dead - - Liver (7)
66/F ERH and
colectomy
4 0 0 7 Dead - - Seeding and regional
LN (7)
54/M ERH, segmental
duodenectomy
4 0 0 16 Dead + + Seeding (14)
53/F HPD 4 1 0 8 Dead - - Seeding (5)
65/F HPD 4 1 0 8 Dead - - Liver (5)
IVb 64/M EC 3 2 0 Para-aortic LN 34 Dead + - Regional LN (22)
58/F EC 2 1 1 S5 (1 lesion) 30 Alive + - Regional LN (20)
44/F ERH 2 1 1 S5/6 (2 lesions) 22 Dead + - Liver (14)
74/F EC 3 1 1 S5 (1 lesion) 109 Alive - - No
55/F ERH 3 1 1 S4 (2 lesions) 39 Alive + - No
57/F LC, seeding
nodule
excision
2 0 1 Seeding
(abdominal
wall, omentum,
diaphragm)
57 Alive - - No
67/F EC 2 1 1 Seeding
(mesentery)
11 Dead + + Liver (6)
60/F EC 3 1 1 Seeding
(omentum)
20 Dead + - Seeding (10)
73/M EC 4 0 1 Seeding
(abdominal
wall)
26 Dead + - Seeding (6)
59/M HPD 4 1 1 Seeding
(mesentery)
11 Alive + - Para-aortic LN (11)
T, tumour; N, node; M, metastasis; M, male; F, female; LN, lymph node; ERH, extended right hemihepatectomy; HPD, hepatopancreatoduodenec-
tomy; EC, extended cholecystectomy; LC, laparoscopic cholecystectomy.
HPB 807
HPB 2012, 14, 805–811 © 2012 International Hepato-Pancreato-Biliary Association
[n = 5; 20.0 months (95% CI 9.3–30.7)] than in those who
underwent palliative surgery [n = 31; 6.0 months (95% CI 3.3–
8.7)]
(P = 0.002).
Of the 16 patients who underwent surgery with curative intent,
13 developed recurrence (liver metastases, n = 5; peritoneal
seeding, n = 5; metastatic lymphadenopathy, n = 3). In the 16
patients with stage IV GB cancer who underwent surgery with
curative intent, median disease-free survival was 7 months (95%
CI 6.7–7.3) and the rate of 1-year disease-free survival was 26.7%.
Univariate and subsequent multivariate analyses of potential
important prognostic factors are shown in Table 3. Univariate
analysis of potentially important factors in the 16 patients who
underwent surgery with curative intent for stage IV GB cancer is
shown in Table 4.
Figure 2 summarizes the treatment scheme for stage IV GB
cancer in this study. In patients with liver metastases, adjuvant
chemotherapy was given to three of the four patients treated with
surgery with curative intent compared with five of the 15 patients
treated palliatively (P = 0.262). In patients with peritoneal seeding,
adjuvant chemotherapy was administered to all patients who
underwent surgery with curative intent (n = 5) and nine of the 27
patients who underwent palliative surgery (P = 0.010).
Discussion
Gallbladder cancers are known to have a dismal prognosis unless
the disease is treated in the early stages.1 Early GB cancers are
usually found incidentally after cholecystectomy conducted as a
result of a GB stone or cholecystitis, and curative resection surgery
results in a favourable outcome.4 However, despite improvements
in diagnostic modalities, the majority of GB cancers are not diag-
nosed until the disease has reached an advanced stage3 and the
prognosis is apparently poor even after radical resection.5,6,13 Thus,
although there are many challenges in improving survival out-
comes in advanced GB cancer patients, some studies have
reported positive results. Since the advantages of radical surgery in
cases of liver invasion were reported,9 the use of extensive surgery
in advanced GB cancer has gained support.5,6,8,12,15 Furthermore,
there are reports of at least 22 patients who have survived for >5
years after aggressive surgery for stage IV GB cancer.13,16 The pos-
sibility of longterm survival after curative surgery in patients with
para-aortic lymph node metastases or isolated liver metastases has
also been suggested.17
However, the use of various staging systems for GB cancer, as
defined by the AJCC,18 the International Union against Cancer
[Union Internationale contre le Cancer (UICC)]19 and the Japa-
nese Society of Biliary Surgery (JSBS),20 causes confusion in the
interpretation of survival outcomes in advanced GB cancer. In
particular, the JSBS staging system20 definitions of T3 and T4
disease differ from those of the AJCC18 and the UICC19 in terms of
the depth of liver invasion. In addition, the tumour–node–
metastasis (TNM) stage used to define stage IV varies across the
systems. In consequence, in stage IV GB cancer defined according
to the JSBS staging system, the curative resection and 5-year sur-
vival rates have been reported to be as high as 66% and 14%,
respectively,12 whereas 5-year survival in patients staged according
to the UICC system is reported to be 3–7%.5,6 Moreover, previous
studies have dealt with limited numbers of patients in whom stage
IV GB cancer with metastatic disease has been resected with cura-
tive intent. This study provides the largest cohort (n = 94) of
patients with stage IV GB cancer, defined according to the seventh
edition of the AJCC staging system,14 to have undergone surgery.
The authors specifically compared survival in patients with locally
advanced stage IV GB cancer (stage IVa) with that in patients with
distant metastases (stage IVb disease).
In this study, overall median survival was 8 months in both
stage IVa and stage IVb GB cancer. Surgery with curative intent
was performed in 16 patients (17.0%), in whom outcomes were
favourable compared with those in patients undergoing palliative
surgery alone. The data in this study show that surgery with
curative intent in locally advanced GB cancer with or without
lymph node metastasis (stage IVa) did not improve survival rates.
This finding confirms previous reports in patients with extensive
nodal metastases or advanced T-stage disease which indicated
that such patients are poor candidates for aggressive surgical
intervention.15,21,22
In general, patients with advanced GB cancer with distant
metastases (including para-aortic lymph node metastases) have
not been thought to benefit from aggressive surgery.10,16 Although
aggressive surgery for GB cancers with liver invasion has been
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Figure 1 Overall survival in stage IV gallbladder cancer after surgery
with curative intent (n = 16; median survival: 19 months) or palliative
surgery (n = 78; median survival: 8 months) (P < 0.001)
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reported to enhance survival outcomes,9,15 it has not been
universally accepted as offering survival benefit.5,6,13 Moreover,
longterm survival after surgical resection in patients with meta-
static disease has rarely been reported.16 However, the current
study shows that a carefully selected subset of patients with
distant metastases (stage IVb disease) demonstrated a significant
survival gain after surgery with curative intent. These included
two longterm survivors, one of whom had a single S5 metastasis
near the GB bed and underwent an extended cholecystectomy in
which the extent of the liver resection included the hepatic meta-
static nodule; this patient was alive and disease-free at 109
months postoperatively. The other patient, in whom three peri-
toneal seeding nodules were found at the abdominal wall,
omentum and diaphragm, underwent cholecystectomy with
seeding nodule excision and was alive and disease-free at 57
months postoperatively. Thus, distant metastases did not appear
to be a negative prognostic factor in overall stage IV GB cancer in
the current study. Additionally, in patients treated with curative
intent, the presence of distant metastases was a positive prognos-
tic factor. Given the prognostic outcome and the pattern of
recurrence, these facts imply that the tumour burden in locally
advanced disease is higher than that in patients with limited
metastatic disease and therefore surgery with curative intent may
be appropriate in selected patients with limited metastatic
disease. This is in line with a recent report by Shimizu et al., who
found that neither hepatic invasion nor liver metastases were
negative prognostic factors in stage IV GB cancer.12 Nishio et al.
also reported a superior survival outcome in patients with para-
aortic lymph node metastases or isolated liver metastases com-
pared with those with other distant metastases.17 Previous
experiences in colorectal cancer23,24 and gastric cancer25,26 indicate
that in GB cancer, resection with curative intent that includes
complete metastatectomy may be beneficial in carefully selected
patients with stage IV disease. Obviously, further prospective
studies with larger study cohorts are needed.
Along with surgery, the provision of adjuvant chemotherapy
was an independent prognostic factor in patients with stage IV GB
cancer.Although the equivalent adjuvant chemotherapy was given
to patients with liver metastases, whether or not they underwent
curative resection, a significantly higher proportion of patients
with peritoneal seeding in the curative resection group received
adjuvant chemotherapy. Unfortunately, there is no established
standard chemotherapy for patients with locally advanced GB
cancer. A recent Phase III study reported improved survival out-
comes after chemotherapy based on cisplatin in combination with
Table 3 Prognostic factor analysis in 94 patients with stage IV gallbladder cancer
Variables Univariate analysis Multivariate analysis
n Median survival, months P-value HR 95% CI P-value
Age, years, <60/60 39/55 8/8 0.172
Sex, male/female 41/53 8/8 0.525
Bilirubin, maximum, mg/dl, 5/>5 77/17 8/9 0.801
CEA, ng/ml, 5/>5 53/37 10/7 <0.001 1.849 1.109–3.084 0.018
CA 19-9, U/ml, 37/>37 35/48 8/8 0.803
Stage, IVa/IVb 16/78 8/8 0.400
Distant metastases, +/- 57/37 8/8 0.426
Resection with curative intent, +/- 16/78 16/8 <0.001 2.042 1.016–4.101 0.045
R0 resection, +/- 15/79 16/8 <0.001
Adjuvant chemotherapy, +/- 30/55 14/7 <0.001 2.367 1.371–4.085 0.002
Histological grade, G1/G2/G3/G4 15/42/25/1 8/9/8/33 0.462
The variables ‘Resection with curative intent’ and ‘R0 resection’ were linearly dependent covariates and their correlation efficient was 0.962
(P < 0.001). In consequence, R0 resection was removed from the multivariate analysis model.
HR, hazard ratio; 95% CI, 95% confidence interval; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9.
Table 4 Prognostic factors in 16 patients with stage IV gallbladder
cancer who underwent surgery with curative intent
Variables n = 16 Median
survival,
months
P-value
Age, years, <60/60 7/9 11/23 0.319
Sex, male/female 6/10 15/20 0.295
Bilirubin, maximum, mg/dl,
5/>5
13/3 20/16 0.608
CEA, ng/ml, 5/>5 14/2 20/8 0.158
CA 19-9, U/ml, 37/>37 7/8 31/11 0.206
Distant metastasis, +/- 9/7 26/8 0.014
Stage, IVa/IVb 6/10 8/26 <0.001
Resection of hepatic metastasis
near GB bed, +/-
4/12 31/11 0.054
Peritoneal implantation, +/- 5/11 20/16 0.808
Adjuvant chemotherapy, +/- 10/6 23/8 0.091
Histological grade, G1/G2/
G3/G4
3/7/4/1 11/23/15/33 0.154
CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9;
GB, gallbladder.
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gemcitabine in advanced biliary tract cancer.27 However, given the
retrospective nature of the present study, it is difficult to evaluate
treatment effects according to the chemotherapeutic agent.
However, these results support those of studies that show the
importance of using a multidiscipline treatment strategy that
includes both surgery and systemic chemotherapy in advanced GB
cancer.28
In summary, the present study found that overall median sur-
vival was 8 months in both stage IVa and stage IVb GB cancers.
Resection with curative intent was performed in 17.0% of
patients with stage IV GB cancer. Resection with curative intent
increased overall survival compared with palliative surgery. The
multivariate analysis indicated the independent prognostic
factors in stage IV GB cancer were preoperative serum CEA
levels, surgery with curative intent and adjuvant chemotherapy.
After resection with curative intent, overall median survival was
8 months in stage IVa and 26 months in stage IVb disease. In
patients with hepatic metastatic nodules near the GB bed or
those with limited numbers of peritoneal implantations, resec-
tion with curative intent provided a significant survival benefit.
Adjuvant chemotherapy made a marginally significant difference
to survival after curative resection. Although this study was not a
prospective comparative study, it affords the conclusions that
surgery with systemic chemotherapy may be beneficial in care-
fully selected stage IVb GB cancer patients.
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